Stifel analyst Dae Gon Ha reiterated a Buy rating and $43.00 price target on Fulcrum Therapeutics (NASDAQ: FULC), following the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE